DIAbetes-PREvention Trial

Phase 4

Completed

• Conditions: pre-diabetici; Heart problems; pre-diabetics; 10011082

• Registration Number: NL-OMON38088
• Lead Sponsor: Isala Klinieken

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 78

Inclusion Criteria

Inclusion criteria ;• • Patients admitted with coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI) (inclusion within 2 month after admission) ;• Age >= 18 years ;• Elevated HbA1c levels (HbA1c > 5.8% or > 40 mmol/mol) on admission ;• Access to a computer with internet connection;• Written informed consent

Exclusion Criteria

Exclusion criteria ;• Known diabetics, with or without anti-diabetic medication ;• Contra-indications for Metformine use as stated in the medication registration;• Life Expectancy <1 yr ;• Physical limitations/restrictions for participation in exercise programme or exercise testing ;• Fasting plasma glucose >= 7.0 mmol/l or HbA1c >= 53

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The reduction in HbA1c at one year in patients with coronary artery disease<br /><br>(PCI or CABG in stable CAD, or post STEMI and post non-STEMI patients)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- hsCRP<br /><br>- LDL cholesterol<br /><br>- MACE at one year FUP<br /><br>- Exercise capacity</p><br>